← All trials
NCT04271839
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- May 31, 2021
- Completion date
- May 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 208
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MundipharmaLead sponsor
- Hospital Virgen de la VictoriaStudy director
- Hospital Joan XXIII de Tarragona, Tarragona, SpainOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- University of SantiagoOverall official - principal investigator
- University of VigoOverall official - principal investigator
- Clinica Universidad de NavarraOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Hospital Universitario Ramon y CajalOverall official - principal investigator
- Hospital La PazStudy director
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- MundipharmaReponsible party - principal investigator
- Virgen del Rocío University Hospital, SevilleOverall official - principal investigator
- Hospital Universitario Virgen MacarenaOverall official - principal investigator
- Hospital Universitario San CecilioOverall official - principal investigator
- Hospital Universitario Lucus AugustiOverall official - principal investigator
- Hospital Universitario de La PlanaOverall official - principal investigator
- Hospital Universitario Infanta LeonorOverall official - principal investigator
- Hospital General Universitario de CastellónOverall official - principal investigator
- Hospital Universitario Nuestra Señora del Perpetuo Socorro de AlbaceteOverall official - principal investigator
- Hospital Universitario de FuenlabradaOverall official - principal investigator
- Hospital Costa del SolOverall official - principal investigator
- Hospital Universitario Central de AsturiasOverall official - principal investigator
- Dynamic SolutionsCollaborator
- Alpha Bioresearch S.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.